Data Quality Notice
Data quality observations on this stock — see hidden fields below.
Reported as ticker: PAR· We're continuously improving data quality. Contact support if this persists.
PAR DRUGS AND CHEM LTD
PAR · General/Diversified · NSE
₹92
Current Market Price
Fair Value (DCF)
₹292
Margin of Safety
+219.5%
Updated just now
YieldIQ Score
72/100
Piotroski F-Score
5/9
Economic Moat
Wide
Confidence
73%
ROE
—
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹113 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.4%
Return on capital employed
EV / EBITDA
4.3×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
—
EBIT covers interest
Current Ratio
3.31×
Short-term liquidity
Asset Turnover
0.84×
Revenue per ₹ of assets
Revenue CAGR (3Y)
10.7%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹91.52
Bear case
₹162.97
MoS +43.8%
Base case
₹292.45
MoS +68.7%
Bull case
₹328.39
MoS +72.1%
Ratio Trends
PAR · last 4 annual periods
ROE
13.5%
ROCE
21.8%
Operating Margin
—
Debt / Equity
—
PE
15.2×
EV / EBITDA
8.2×
Historical Financials
PAR · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹74.2 Cr | ₹95.1 Cr | ₹95.1 Cr | ₹101 Cr | +10.7% |
| EBITDA | ₹16.4 Cr | ₹18.3 Cr | ₹23.0 Cr | ₹21.6 Cr | +9.7% |
| EBIT | ₹13.2 Cr | ₹15.2 Cr | ₹19.6 Cr | — | +14.3% |
| PAT | ₹9.2 Cr | ₹11.3 Cr | ₹14.5 Cr | ₹13.4 Cr | +13.2% |
| EPS (diluted) | ₹7.49 | ₹9.21 | ₹11.78 | — | +16.3% |
| CFO | ₹7.6 Cr | ₹13.4 Cr | ₹20.2 Cr | ₹16.2 Cr | +28.5% |
| CapEx | ₹-3.2 Cr | ₹-7.6 Cr | ₹-6.1 Cr | ₹-1.2 Cr | — |
| FCF | ₹4.4 Cr | ₹5.7 Cr | ₹14.2 Cr | ₹14.9 Cr | +50.1% |
| Total Assets | ₹78.7 Cr | ₹88.9 Cr | ₹102 Cr | ₹119 Cr | +14.9% |
| Total Debt | ₹0.0 Cr | ₹0.0 Cr | ₹0.0 Cr | ₹0.0 Cr | — |
| Shareholders' Equity | ₹59.9 Cr | ₹71.2 Cr | ₹85.6 Cr | ₹99.0 Cr | +18.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
PAR vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| BALPHARMA BALPHARMA | — | — | Pending | 9.3% | — |
| VAISHALI VAISHALI | — | — | Pending | 1.3% | — |
| KREBSBIO KREBSBIO | — | — | Pending | 18.4% | — |
| ALPA ALPA | — | — | Pending | 11.4% | — |
| NATCAPSUQ NATCAPSUQ | — | — | Pending | 0.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for PAR in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. PAR DRUGS AND CHEM LTD (PAR.NS) trades at 91.52 vs a model fair value of 292.45, a gap of 219.5%. Piotroski F-score: 5/9. Moat label: Wid...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of PAR →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for PAR →
Compare
Head-to-head with peers
Compare PAR side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse PARNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.